- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1741-7015
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Advances in Alzheimer’s Disease Drug Development ; volume:13 ; number:1 ; day:25 ; month:3 ; year:2015 ; pages:1-7 ; date:12.2015
BMC medicine ; 13, Heft 1 (25.3.2015), 1-7, 12.2015
- Creator
-
Rafii, Michael S.
- Contributor
-
Aisen, Paul S.
SpringerLink (Online service)
- DOI
-
10.1186/s12916-015-0297-4
- URN
-
urn:nbn:de:1111-201611047092
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 8:53 AM UTC
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rafii, Michael S.
- Aisen, Paul S.
- SpringerLink (Online service)
Other Objects (12)
Advances in Drug Therapy for Alzheimer’s Disease
The Alzheimer’s disease drug development landscape
Alzheimer’s Disease Drug Development Pipeline 2020
Geroscience and Alzheimer’s Disease Drug Development
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies
Advances in the development of new biomarkers for Alzheimer’s disease
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Advances in Drug Therapy for Alzheimer’s Disease
The Alzheimer’s disease drug development landscape
Alzheimer’s Disease Drug Development Pipeline 2020
Geroscience and Alzheimer’s Disease Drug Development
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies
Advances in the development of new biomarkers for Alzheimer’s disease
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Advances in Drug Therapy for Alzheimer’s Disease
The Alzheimer’s disease drug development landscape
Alzheimer’s Disease Drug Development Pipeline 2020
Geroscience and Alzheimer’s Disease Drug Development
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies
Advances in the development of new biomarkers for Alzheimer’s disease
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline